WINNIPEG, MANITOBA -- (MARKET WIRE) -- October 11, 2006 -- Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and validation of cancer biomarkers for use in developing diagnostic tools and therapeutic products, is pleased to announce that it has successfully detected the primary protein biomarker from its prostate cancer diagnostic, using an ELISA based immunoassay.
